Thomas G. Wiggans Sells 11,000 Shares of Dermira Inc. (DERM) Stock
Dermira Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 11,000 shares of Dermira stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $34.60, for a total value of $380,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Dermira Inc. (NASDAQ:DERM) opened at 34.77 on Wednesday. Dermira Inc. has a 12-month low of $17.42 and a 12-month high of $36.16. The stock’s market capitalization is $1.23 billion. The company has a 50-day moving average price of $33.01 and a 200-day moving average price of $29.42.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. Analysts expect that Dermira Inc. will post ($3.39) earnings per share for the current fiscal year.
A number of research firms have recently weighed in on DERM. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dermira in a research report on Wednesday, September 21st. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $41.00.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio raised its position in shares of Dermira by 72.6% in the second quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 5,300 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock worth $39,333,000 after buying an additional 55,991 shares in the last quarter. Hamilton Lane Advisors LLC raised its position in shares of Dermira by 179.5% in the second quarter. Hamilton Lane Advisors LLC now owns 34,615 shares of the biopharmaceutical company’s stock worth $1,099,000 after buying an additional 22,229 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Dermira during the first quarter worth $2,482,000. Finally, Geode Capital Management LLC raised its position in shares of Dermira by 7.8% in the first quarter. Geode Capital Management LLC now owns 123,424 shares of the biopharmaceutical company’s stock worth $2,552,000 after buying an additional 8,952 shares in the last quarter. 82.46% of the stock is currently owned by institutional investors and hedge funds.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.